February 24, 2021
LA JOLLA—The Salk Institute received a matching $1 million gift from the BioMed Realty Management Team, which was used to fund the recruitment of award-winning cancer researcher Christina Towers and to support her research and that of the 索尔克癌症中心. The challenge match—where BioMed Realty matches, dollar for dollar, up to $1 million—will also support Salk’s bold 攻克癌症倡议, which is harnessing cutting-edge approaches to fight some of the deadliest cancers, including pancreatic, ovarian, lung, colon, brain (glioblastoma) and triple-negative breast cancer.
Spearheading the gift was BioMed Realty’s president and CEO, Tim Schoen, who is a Salk Trustee and chairman of the Institute’s Conquering Cancer Initiative Advisory Committee.
“The BioMed Management team is excited to support a world class researcher such as Dr. Towers as she joins the leading scientists at Salk to tackle cancer,” says Schoen. “Now, more than ever, investments in innovative science are needed to help win the war against deadly diseases.”
Towers, who joined Salk’s renowned NCI-designated Cancer Center as an assistant professor in December, examines how cancer cells recycle both their own nutrients and the power-generating structures called mitochondria in order to survive. By using a combination of gene-editing techniques, light-based genetic manipulation (optogenetics), three-dimensional miniature organs (“organoids”), and detailed imaging, she aims to identify the best ways to target the recycling pathways that tumors use to survive. Her research aims to lead to new targeted cancer therapies that can improve patient outcomes and survival. Read more about her work here: https://www.salk.edu/scientist/christina-towers/.
“The Institute is incredibly grateful for the support and leadership shown by BioMed Realty,” says Salk President 鲁斯蒂·盖奇. “This generous gift enabled Salk to add an innovative cancer researcher to our faculty. We are thrilled to have Christie working with us.”
宣传办公室
电话:(858) 453-4100
press@salk.edu
萨尔克研究所是一个独立的非营利性研究机构,由首个安全有效的脊髓灰质炎疫苗的研发者乔纳斯·索尔克于1960年创立。该研究所的使命是推动以合作、敢于冒险为特点的基础性研究,以应对癌症、阿尔茨海默病和农业脆弱性等社会最紧迫的挑战。这项基础科学支撑着所有的转化研究,产生有助于全球新药和创新的见解。.